© 2004 European Society for Medical Oncology
Original Article |
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
Divisions of 1Medical Oncology and 2 Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
* Correspondence to: Dr Kerry J. Savage, B.C. Cancer Agency, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, Canada. Tel: +1-604-877-6000; Fax: +1-604-877-0585; Email: ksavage{at}bccancer.bc.ca
Background: All peripheral T-cell lymphomas (PTCLs) diagnosed at a single institution were evaluated to determine the unique clinical features and outcome of specific entities and test the predictive validity of the International Prognostic Index (IPI).
Patients and methods: Cases of PTCL seen at the British Columbia Cancer Agency between 1981 and 2000 were identified. Pathologic material was re-assessed and classified according to the WHO classification, and patients were staged and treated uniformly according to era-specific guidelines. In total, there were 199 patients with PTCL and the most common subtypes were peripheral T-cell lymphoma unspecified (PTCL-US) (59%), anaplastic large-cell lymphoma, systemic type (ALCL) (17%) and extranodal NK/T-cell lymphoma, nasal and nasal-type (NASAL) (9%). Most patients were treated with CHOP-type chemotherapy.
Results: Three distinct prognostic subgroups were notable on survival analysis: favorable (cutaneous ALCL), 5-year overall survival (OS) 78%; intermediate [PTCL, ALCL and angioimmunoblastic lymphoma (AILT)], 5-year OS 35–43%; unfavorable [NASAL and enteropathy-type T-cell lymphoma (ETTL)], 5-year OS 22–24%. Furthermore, in PTCL-US and ALCL clinical separation of patients into good risk (IPI 0,1) and poor risk (IPI 
2) subsets was demonstrated.
Conclusions: A large proportion of PTCL patients have poor risk disease and/or a histologically aggressive subtype with frequent relapse and unfavorable outcome. For these patients, treatment with CHOP chemotherapy is only minimally effective and new strategies need to be developed, an effort that will require a multi-institution international collaboration due to the rarity of most subtypes.
Key words: peripheral, T-cell lymphomas, WHO classification, IPI
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Le Gouill, N. Milpied, A. Buzyn, R. Peffault De Latour, J.-P. Vernant, M. Mohty, M.-P. Moles, K. Bouabdallah, C.-E. Bulabois, J. Dupuis, et al. Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire J. Clin. Oncol., May 10, 2008; 26(14): 2264 - 2271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma Ann. Onc., May 1, 2008; 19(5): 958 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Alekshun, D. Rezania, E. Ayala, H. Cualing, and L. Sokol Skeletal Muscle Peripheral T-Cell Lymphoma J. Clin. Oncol., January 20, 2008; 26(3): 501 - 503. [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Halfdanarson, M. R. Litzow, and J. A. Murray Hematologic manifestations of celiac disease Blood, January 15, 2007; 109(2): 412 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study Blood, December 15, 2006; 108(13): 4163 - 4169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Went, C. Agostinelli, A. Gallamini, P. P. Piccaluga, S. Ascani, E. Sabattini, F. Bacci, B. Falini, T. Motta, M. Paulli, et al. Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score J. Clin. Oncol., June 1, 2006; 24(16): 2472 - 2479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-X. Li, B. Yao, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, S.-L. Wang, X.-F. Liu, L.-Q. Zhou, X.-H. He, et al. Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma J. Clin. Oncol., January 1, 2006; 24(1): 181 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Jaffe Pathobiology of Peripheral T-cell Lymphomas Hematology, January 1, 2006; 2006(1): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Greer Therapy of Peripheral T/NK Neoplasms Hematology, January 1, 2006; 2006(1): 331 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Savage Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types) Hematology, January 1, 2005; 2005(1): 267 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Armitage, J. M. Vose, and D. D. Weisenburger Towards understanding the peripheral T-cell lymphomas Ann. Onc., October 1, 2004; 15(10): 1447 - 1449. [Full Text] [PDF]
|
|